DE59309727D1 - Methandiphosphonsäure-Formulierungen mit Ionenaustauschern - Google Patents

Methandiphosphonsäure-Formulierungen mit Ionenaustauschern

Info

Publication number
DE59309727D1
DE59309727D1 DE59309727T DE59309727T DE59309727D1 DE 59309727 D1 DE59309727 D1 DE 59309727D1 DE 59309727 T DE59309727 T DE 59309727T DE 59309727 T DE59309727 T DE 59309727T DE 59309727 D1 DE59309727 D1 DE 59309727D1
Authority
DE
Germany
Prior art keywords
diphosphonic acid
ion exchangers
acid formulations
disodium
methane diphosphonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE59309727T
Other languages
English (en)
Inventor
Satish Chandra Khanna
Jonathan Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE59309727D1 publication Critical patent/DE59309727D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
DE59309727T 1992-04-15 1993-04-06 Methandiphosphonsäure-Formulierungen mit Ionenaustauschern Expired - Fee Related DE59309727D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH124792 1992-04-15

Publications (1)

Publication Number Publication Date
DE59309727D1 true DE59309727D1 (de) 1999-09-16

Family

ID=4205927

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59309727T Expired - Fee Related DE59309727D1 (de) 1992-04-15 1993-04-06 Methandiphosphonsäure-Formulierungen mit Ionenaustauschern

Country Status (20)

Country Link
US (1) US5344825A (de)
EP (1) EP0566535B1 (de)
JP (1) JP3970941B2 (de)
KR (1) KR100307786B1 (de)
AT (1) ATE183096T1 (de)
AU (1) AU665814B2 (de)
CA (1) CA2093946C (de)
DE (1) DE59309727D1 (de)
DK (1) DK0566535T3 (de)
ES (1) ES2137241T3 (de)
FI (1) FI110920B (de)
GR (1) GR3031645T3 (de)
HU (1) HU219022B (de)
IL (1) IL105382A (de)
MX (1) MX9302151A (de)
NO (1) NO306978B1 (de)
NZ (1) NZ247398A (de)
PH (1) PH30733A (de)
TW (1) TW237386B (de)
ZA (1) ZA932613B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
DE69826660T2 (de) * 1997-06-11 2005-10-06 The Procter & Gamble Company, Cincinnati Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
WO2002058708A1 (en) * 2001-01-23 2002-08-01 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1396263A1 (de) * 2002-08-09 2004-03-10 Warner-Lambert Company Filmüberzüge für Tabletten oder Caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
CN1649598B (zh) * 2002-12-20 2011-12-07 弗·哈夫曼-拉罗切有限公司 高剂量伊班膦酸制剂
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP4896480B2 (ja) * 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 陰イオン交換樹脂の粒子状組成物
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CA3077421A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System Inhalable composition of clofazimine and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
JPS57177012A (en) * 1981-04-23 1982-10-30 Sumitomo Chem Co Ltd Preparation of chelate resin
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
IL84494A (en) * 1986-11-21 1992-08-18 Ciba Geigy Ag Heteroaryl substituted aminomethane-diphosphonic acids,their preparation and pharmaceutical compositions containing them
US5057505A (en) * 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate

Also Published As

Publication number Publication date
KR100307786B1 (ko) 2001-11-30
NO931367L (no) 1993-10-18
HUT63766A (en) 1993-10-28
DK0566535T3 (da) 2000-03-06
ES2137241T3 (es) 1999-12-16
NO306978B1 (no) 2000-01-24
EP0566535B1 (de) 1999-08-11
JPH069408A (ja) 1994-01-18
MX9302151A (es) 1993-10-01
HU219022B (hu) 2001-04-28
TW237386B (de) 1995-01-01
CA2093946C (en) 2005-07-05
GR3031645T3 (en) 2000-02-29
AU3696193A (en) 1993-10-21
FI931633A0 (fi) 1993-04-08
CA2093946A1 (en) 1993-10-16
ATE183096T1 (de) 1999-08-15
EP0566535A1 (de) 1993-10-20
IL105382A0 (en) 1993-08-18
US5344825A (en) 1994-09-06
PH30733A (en) 1997-10-17
FI110920B (fi) 2003-04-30
IL105382A (en) 1998-06-15
KR940005268A (ko) 1994-03-21
NZ247398A (en) 1995-07-26
HU9301088D0 (en) 1993-06-28
ZA932613B (en) 1993-10-26
FI931633A (fi) 1993-10-16
AU665814B2 (en) 1996-01-18
JP3970941B2 (ja) 2007-09-05
NO931367D0 (no) 1993-04-14

Similar Documents

Publication Publication Date Title
DE59309727D1 (de) Methandiphosphonsäure-Formulierungen mit Ionenaustauschern
ZA892557B (en) Pharmaceutical composition for oral administration,based on a diphosphonic acid derivative
IL105403A0 (en) Pharmaceutical preparation and process for its manufacture
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
WO2000018447A3 (en) Multiplex drug delivery system suitable for oral administration
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
PL341055A1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
HU0200688D0 (en) Pharmaceutical formulations with improved release containing solid salts of racemic thioctic acid
WO2000001372A3 (en) Chewable oral unit dosage
CA2311024A1 (en) Pharmaceutical composition for oral administration of chelating agents
HK1001822A1 (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
ES2118451T3 (es) Preparado medicamentoso oral que contiene diclofenaco sodico y un acido organico.
AU1283188A (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable nondigestible anion exchange resin
Lessard Short Pieces for Piano (For Aaron)
Kuzmin et al. Pharmacokinetics of zixorine administered in single and multiple doses.
Ferrari et al. Eosinophilia associated with glaphenin.
EG21151A (en) A convenient facile synthesis of 2,6-dichlorod-iphenylamine the key intermediate for the synthesis of 0-(2,6 dichloroanilino) phenylacetic acid diclofenac voltaren) utilizing the firstly reported n- formyl-2,6-dichlorodiphenylamine
EP0356254A3 (de) Pharmazeutische Formulierungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee